EP4051343A1 — Haptic feedback of an electronic medical device
Assigned to Sanofi SA · Expires 2022-09-07 · 4y expired
What this patent protects
Implementations of the present disclosure are directed to a medical handheld device that includes an actuating feature configured to generate a trigger signal, a sensor configured to detect a functionality of the medical handheld device in response to the trigger signal, and a ha…
USPTO Abstract
Implementations of the present disclosure are directed to a medical handheld device that includes an actuating feature configured to generate a trigger signal, a sensor configured to detect a functionality of the medical handheld device in response to the trigger signal, and a haptic source configured to generate a haptic signal including information associated with the functionality of the medical handheld device.
Drugs covered by this patent
- naloxone-hydrochloride (Naloxone Hydrochloride) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.